GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONSTS FOR THE TREATMENT OF NONALOCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS: A META-ANALYSIS AND SYSTEMATIC REVIEW

被引：0
|
作者：
Sayeh, Wasef
Dhoop, Sudheer M.
Sidiki, Sabeen
Beran, Azizullah
Abuhelwa, Ziad
Safi, Mohammad
Alqadi, Mohammad
Sajdeya, Omar
Battepati, Dhanushya
Malhas, Saif-Eddin
Stanely, Sara
Aziz, Muhammad
Alastal, Yaseen
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1569
引用
收藏
页码：S1374 / S1375
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis
    Dong, Yajie
    Lv, Qingguo
    Li, Sheyu
    Wu, Yuan
    Li, Ling
    Li, Juan
    Zhang, Fang
    Sun, Xin
    Tong, Nanwei
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2017, 41 (03) : 284 - 295
  • [2] Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis
    Borodavkin, Petr
    Sheridan, William
    Coelho, Claudia
    Ostarijas, Eduard
    Zair, Zoulikha M.
    Miras, Alexander D.
    McGowan, Barbara
    le Roux, Carel W.
    Vincent, Royce P.
    Dimitriadis, Georgios K.
    DIABETES OBESITY & METABOLISM, 2022, 24 (02): : 337 - 342
  • [3] Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis
    Wong, Chloe
    Lee, Ming Hui
    Yaow, Clyve Yu Leon
    Chin, Yip Han
    Goh, Xin Lei
    Ng, Cheng Han
    Lim, Amanda Yuan Ling
    Muthiah, Mark Dhinesh
    Khoo, Chin Meng
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [4] Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
    Sofogianni, Areti
    Filippidis, Athanasios
    Chrysavgis, Lampros
    Tziomalos, Konstantinos
    Cholongitas, Evangelos
    WORLD JOURNAL OF HEPATOLOGY, 2020, 12 (08) : 493 - 505
  • [5] Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
    Areti Sofogianni
    Athanasios Filippidis
    Lampros Chrysavgis
    Konstantinos Tziomalos
    Evangelos Cholongitas
    World Journal of Hepatology, 2020, 12 (08) : 493 - 505
  • [6] Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
    Wang, Xing-Chun
    Gusdon, Aaron M.
    Liu, Huan
    Qu, Shen
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (40) : 14821 - 14830
  • [7] Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
    Xing-Chun Wang
    Aaron M Gusdon
    Huan Liu
    Shen Qu
    World Journal of Gastroenterology, 2014, (40) : 14821 - 14830
  • [8] Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease
    Junker, Anders E.
    Gluud, Lise L.
    van Hall, Gerrit
    Holst, Jens J.
    Knop, Filip K.
    Vilsboll, Tina
    JOURNAL OF HEPATOLOGY, 2016, 64 (04) : 908 - 915
  • [9] The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials
    Fan, Simin
    Shi, Xiaoyan
    Yao, Jia
    Zhong, Min
    Feng, Peimin
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2020, 112 (08) : 627 - 635
  • [10] Use of thiazolidinediones and glucagon-like peptide-1 receptor agonists and the risk of non-alcoholic fatty liver disease
    Driessen, Johanna H. M.
    van Dalem, Judith
    Burden, Andrea M.
    Stehouwer, Coen D. A.
    Klungel, Olaf H.
    de Vries, Frank
    Brouwers, Martijn C. G. J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 128 - 128
12345